Superscan in First Posttherapeutic 177 Lu-PSMA Scan

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Prostate cancer can progress to castration-resistant prostate cancer (CRPC).
• Extensive skeletal metastases are a common complication of advanced CRPC.
• 177 Lu-PSMA-617 targeted radionuclide therapy offers a novel treatment approach.

Purpose of the Study:

• To evaluate the effectiveness of 177 Lu-PSMA-617 therapy in a patient with metastatic CRPC.
• To assess treatment response using post-therapeutic whole-body imaging.

Main Methods:

• A 70-year-old male patient with CRPC and extensive skeletal metastases received 4 cycles of 177 Lu-PSMA-617 therapy.
• Whole-body 177 Lu-PSMA scans were performed after the first and fourth cycles.
• Response was evaluated based on changes in skeletal lesion uptake and organ uptake, using RECIP 1.0 criteria.

Main Results:

• Initial scan after cycle 1 showed diffuse skeletal lesions with minimal kidney and salivary gland uptake.
• Post-fourth cycle scan demonstrated complete resolution of skeletal metastases.
• Normal PSMA uptake in kidneys and salivary glands was observed after 4 cycles.
• Patient achieved a complete response according to RECIP 1.0 criteria.

Conclusions:

• 177 Lu-PSMA-617 therapy is highly effective in managing extensive skeletal metastases in CRPC.
• Targeted radionuclide therapy can lead to complete remission of metastatic disease.
• This approach demonstrates favorable safety with normal organ uptake post-treatment.